Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Nurse Prescribing 2017; 14 (10): p53-58
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Nurse Prescribing 2017; 14 (10): p53-58
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Practice Nursing 2017; 28 (4): p148-53
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 4th April 2016, p16-19
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 2nd May 2016, p18-24
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 15th February 2016, p17-22
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 6th June 2016, p26-29
Type of publication:
Journal article
Author(s):
*Dr David Morris and Dr Sarah Morris
Citation:
Independent Nurse, 18th July 2016, p 22-26
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 1st June 2015, p31-33
Type of publication:
Journal article
Author(s):
*Dr David Morris
Citation:
Independent Nurse, 7th December 2015, p 22-26
Type of publication:
Journal article
Author(s):
*Morris, David
Citation:
Journal of Diabetes Nursing; Jun 2017; vol. 21 (no. 5); p. 162-167
Abstract:
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are once-daily oral agents effective in treating hyperglycaemia in people with type 2 diabetes, with additional benefits including weight loss and a low risk of hypoglycaemia. This review provides a basic guide to the SGLT2 inhibitors licensed in the UK, including their mechanism of action, benefits, adverse effects and limitations, and place in treatment. Advice on avoiding the rare but serious adverse effect of diabetic ketoacidosis is also provided.
Link to full-text:Â http://www.thejournalofdiabetesnursing.co.uk/media/content/_master/4984/files/pdf/jdn_21-5_162-7.pdf